Prevalence, Risk Factors, and Outcomes of Platelet Transfusion Refractoriness in Critically Ill Patients: A Retrospective Cohort Study
Table 3
Prevalence of platelet refractoriness based on platelet increment (PI) and different cutoffs for the corrected count index (CCI), in different patient subgroups and according to the platelet product types and the time interval between platelet transfusion and the posttransfusion platelet count.
Prevalence of platelet refractoriness
PI < 10000 × 106/L
CCI <5000
All patients (N = 259)
54.8%
57.0%
Admission category
Medical (N = 220)
56.8%
58.5%
Surgical (N = 30)
53.3%
60%
Trauma (N = 9)
11.1%
11.1%
Admitting service
Internal medicine (N = 74)
54.5%
56.8%
Hematology/oncology (N = 72)
58.9%
56.9%
Hepatology/liver transplant (N = 46)
69.6%
71.7%
General surgery (N = 37)
43.2%
45.9%
Splenomegaly∗ (N = 65)
61.5%
64.6%
No splenomegaly (N = 113)
46.0%
50%
Platelet product type
Apheresis (N = 139∗∗)
62.6%
64%
Apheresis-irradiated (N = 195∗∗)
46.9%
47.7%
Pooled (N = 747∗∗)
59.1%
61.6%
Pooled-irradiated (N = 179∗∗)
47.3%
50.3%
Mixed∗∗∗ (N = 90∗∗)
48.4%
65.6%
Time interval between platelet transfusion and the posttransfusion platelet count
<3 hours (N = 319∗∗)
55.4%
57.4% (63.9% for CCI <7500)
3–6 hours (N = 583∗∗)
51.3%
55.2%
7–12 hours (N = 292∗∗)
61.0%
63.4%
>12 hours (N = 113∗∗)
60.3%
63.7% (61.1% for CCI <4500)
∗Spleen size was known in 178 patients. For the calculation of percentages, only valid observations are used in the numerator and denominator. ∗∗Transfusion episodes. ∗∗∗Mixed indicates aggregate transfusions that were derived from transfusions with 2 or more different platelet products.
